Studies Of The Effects Of Asymmetric Hearing Loss On The Brain
Funder
National Health and Medical Research Council
Funding Amount
$920,076.00
Summary
Hearing loss impairs the normal development and maintenance of auditory pathways. Irreversible pathologies persist when hearing is not restored in a timely manner. While cochlear implantation is the accepted treatment for profound sensorineural hearing loss, there is significant variability in outcomes. Some of this variability is linked to the degree of hearing asymmetry. Thus, we propose to study brain changes in the auditory system that accompany asymmetric hearing impairment.
Using Stem Cells And Bioengineered Scaffolds To Promote Regeneration Following Necrotic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$710,857.00
Summary
A number of injuries, including stroke, result in tissue loss. Consequently promoting repair will require restoration of tissue structure, replacement cells and a supportive environment to promote integration of these new cells. This study will engineer and develop novel scaffolds that can replace tissue whilst additionally providing physical and chemical support for newly implanted stem cells. This work will be conducted in an animal model of stroke.
Standardising Protocols For The Differentiation And Integration Of Human Pluripotent Stem Cell-derived Neural Transplants In Parkinson's Disease
Funder
National Health and Medical Research Council
Funding Amount
$987,664.00
Summary
Clinical trials have shown that transplanting dopamine neurons (specific nerve cells) into the brain of Parkinson’s disease patients can improve symptoms. Trials use fetal tissue for implantation, which is unsustainable and highly variable. This proposal will examine stem cells as an alternative. We will establish a reliable protocol to instruct human stem cells to become dopamine neurons, develop methods to select these cells and, examine the integration of these transplanted cells in the brain
Centre For Research Excellence In Stroke Rehabilitation And Brain Recovery
Funder
National Health and Medical Research Council
Funding Amount
$2,595,746.00
Summary
The Centre of Research Excellence in Stroke Rehabilitation and Brain Recovery will transform the stroke research and practice landscape in Australia, and accelerate the development of new interventions strongly supported by neuroscience. This unique collaboration will improve patient selection and rehabilitation research methods, create a training culture for the next generation of rehabilitation researchers and effectively implement proven cost effective interventions for Australians.
Modifiable Risks And Interventions For Cognitive Decline, Depression And Dementia In Older People
Funder
National Health and Medical Research Council
Funding Amount
$430,055.00
Summary
This research proposal will explore the modifiable risk factors for cognitive decline (ie. changes in memory and thinking functions) in older people. It will examine the pertinence of critical contributors to glial-neuronal networks including depression, cardiovascular disease, sleep-wake systems, mental and physical exercise, inflammatory processes and diet, as well as test interventions that target these risk factors. It will use sophisticated brain scanning methods to examine which factors pr ....This research proposal will explore the modifiable risk factors for cognitive decline (ie. changes in memory and thinking functions) in older people. It will examine the pertinence of critical contributors to glial-neuronal networks including depression, cardiovascular disease, sleep-wake systems, mental and physical exercise, inflammatory processes and diet, as well as test interventions that target these risk factors. It will use sophisticated brain scanning methods to examine which factors promote neuroplasticity.Read moreRead less
IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES
Funder
National Health and Medical Research Council
Funding Amount
$7,212,064.00
Summary
Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using ....Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.Read moreRead less